All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Mayo Clinic Lymphoma eTumor Board | Spontaneous regression in a DLBCL, EBV+ patient
Featured:
Grzegorz NowakowskiThis case study discusses the management of a patient with spontaneous regression of diffuse large B-cell lymphoma (DLBCL) with Hans non-germinal center type and double expressor.
This patient case study has been graciously provided to the Lymphoma Hub by the Mayo Clinic Lymphoma eTumor Board (July 18, 2018). The treatment options discussed in this video represent the opinion of the Mayo Clinic experts based on North-America guidelines, drug approvals in the US or clinical trials.
For more information, expert opinions and case studies in Lymphoma, please visit the Lymphoma Hub homepage.
Mayo Clinic Lymphoma eTumor Board | Spontaneous regression in a DLBCL, EBV+ patient